RayKnowChina Research Map
Shortlist0

Beijing

China-Japan Friendship Hospital

中日友好医院

Listed for 19 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at China-Japan Friendship Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌5 papers led
  2. Stomach cancer胃癌13 papers led
  3. Osteosarcoma骨肉瘤2 papers led
  4. Multiple myeloma多发性骨髓瘤2 papers led
  5. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
  6. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病6 papers led
  7. IgG4-related diseaseIgG4相关性疾病0 papers led
  8. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
  9. Takayasu arteritis大动脉炎0 papers led1 open trial led
  10. Idiopathic pulmonary fibrosis特发性肺纤维化19 papers led
  11. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病0 papers led
  12. Spinal muscular atrophy脊髓性肌萎缩症1 paper led
  13. Fabry disease法布雷病1 paper led
  14. Pompe disease庞贝病0 papers led
  15. Duchenne muscular dystrophy杜氏肌营养不良0 papers led
  16. IgA nephropathyIgA 肾病9 papers led
  17. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  18. Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led
  19. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Nasopharyngeal carcinoma, Hepatocellular carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Hepatic echinococcosis, Amyotrophic lateral sclerosis, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 5 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 1120242025: 002025

13 hospitals in Beijing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomics

Over half of these papers are lab or animal studies.

Papers it led5
  1. An emerging biomarker for the diagnosis and treatment of esophageal squamous cell carcinoma - Aurora A.2024Computers in biology and medicine
  2. MARCKSL1 interacted with F-actin to promote esophageal squamous cell carcinoma mobility by modulating the formation of invadopodia.2023Cancer medicineFree full text
  3. E2F1-activated LINC01224 drives esophageal squamous cell carcinoma cell malignant behaviors via targeting miR-6884-5p/DVL3 axis and activating Wnt/β-catenin signaling pathway.2022Pathology, research and practice
  4. The evidence gap between alcohol consumption and oesophageal squamous cell carcinoma in east Africa.2022The Lancet. Global health
  5. Novel lncRNA Panel as for Prognosis in Esophageal Squamous Cell Carcinoma Based on ceRNA Network Mechanism.2021Computational and mathematical methods in medicineFree full text
More papers found outside PubMed (not counted)7
  1. Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation2023Figsharedataset
  2. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  3. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  4. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  5. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  6. Additional file 3 of Characteristics and interplay of esophageal microbiota in esophageal squamous cell carcinoma2022Figsharedataset
  7. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 13 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
13
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 4420212022: 1120222023: 2220232024: 1120242025: 552025

15 hospitals in Beijing for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AIChemotherapy & combined treatmentSurgery
Departments in papersMedical oncologySurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicinePathology / laboratory medicine
Papers it led13
  1. High sodium intake: a silent killer driving global gastric cancer burden.2025BMC cancerFree full text
  2. Circular RNA circPFKP suppress gastric cancer progression through targeting miR-346/CAMD3 axis.2025Experimental cell research
  3. Identification and validation of biomarkers in gastric cancer-associated membranous nephropathy: Insights from comprehensive bioinformatics analysis and machine learning.2025Frontiers in immunologyFree full text
  4. Risk assessment of type I gastric neuroendocrine tumors based on endoscopic and clinical features of autoimmune gastritis.2025World journal of gastroenterologyFree full text
  5. Evaluating the efficacy and safety of neoadjuvant immunochemotherapy versus chemotherapy in locally advanced gastric cancer undergoing radical gastrectomy: a retrospective study.2025World journal of surgical oncologyFree full text
  6. HCA-DAN: hierarchical class-aware domain adaptive network for gastric tumor segmentation in 3D CT images.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  7. Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study.2023BMC gastroenterologyFree full text
  8. Prediction of presurgical metabolic syndrome for gastric cancer-specific mortality is more evident in smokers: The FIESTA study.2023Cancer medicineFree full text
  9. Predictive value of N6-methyladenosine (m6A)-related genes for prognosis and correlation with tumor microenvironment in gastric cancer.2022Chinese medical journalFree full text
  10. Circulating miRNA-202-3p is a potential novel biomarker for diagnosis of type 1 gastric neuroendocrine neoplasms.2021BMC gastroenterologyFree full text
  11. Ectopic Pancreatitis in the Gastric Antrum Mimicking Malignancy on FDG PET/CT.2021Clinical nuclear medicine
  12. A Systematic Review and Meta-Analysis of the Effects of Perioperative Immunonutrition in Gastrointestinal Cancer Patients.2021Nutrition and cancer
  13. Clinicopathological characteristics and prognosis of 232 patients with poorly differentiated gastric neuroendocrine neoplasms.2021World journal of gastroenterologyFree full text
Chinese-language papers (not in the count)1
  1. [Difficulties and challenges in pathological diagnosis of gastrointestinal pancreatic neuroendocrine tumors].2022Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status2
  1. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  2. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

15 hospitals in Beijing for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis, MRD & risk
Departments in papersENT / head & neck surgery

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

11 hospitals in Beijing for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis & prognosisEBV & infection triggers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 6 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.2%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 332025

12 hospitals in Beijing for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRelapse preventionAcute attack treatmentAntibodies & diagnosis
Departments in papersNeurologyOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led no English-language PubMed papers on IgG4-related disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

11 hospitals in Beijing for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

13 hospitals in Beijing for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution

30 hospitals in Beijing for Takayasu arteritis108 hospitals in China for Takayasu arteritis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement
    Phase
    Not given
    Started
    2016-01
    Registry
    NCT07184814

    Age 18 years to Not stated (registered criteria)

    Led by China-Japan Friendship HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [A case report of prolonged pneumonia].2024Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
Earlier papers (2016–2020)1
  1. Evaluation of takayasu arteritis with delayed contrast-enhanced MR imaging by a free-breathing 3D IR turbo FLASH.2017Medicine
All its trials on ClinicalTrials.gov, any status1
  1. Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries InvolvementRecruitingNCT07184814Lead sponsorStart 2016-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 19 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.9%.

Papers led
19
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 4420222023: 4420232024: 2220242025: 662025

27 hospitals in Beijing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
    Phase
    Phase 3
    Started
    2025-10
    Registry
    NCT07082842

    Age 40 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  2. Recruiting
    A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07464912

    Age 40 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineClinical trials / research unit
Papers it led19
  1. Bidirectional Mendelian Randomization Study: Unraveling the Link Between Idiopathic Pulmonary Fibrosis and Cardiovascular Disease.2026Annals of human genetics
  2. Developing and Validation of a Multimodal-Based Machine Learning Model for Diagnosis of Usual Interstitial Pneumonia: A Prospective Multicenter Study.2026Chest
  3. A novel lncRNA ABCE1-5 regulates pulmonary fibrosis by targeting KRT14.2025American journal of physiology. Cell physiology
  4. Small airway lesions appear with the course of IPF and relate to the severity of pulmonary fibrosis progression.2025BMC pulmonary medicine
  5. Evaluation of respiratory muscle dysfunction in patients with idiopathic pulmonary fibrosis: a prospective observational study with magnetic resonance imaging.2025BMC pulmonary medicine
  6. Baseline total lung capacity and all-cause mortality in restrictive pulmonary disorders: a meta-analysis.2025BMC pulmonary medicine
  7. Long non-coding RNA HAGLR: The potential biomarker plays an important role in idiopathic pulmonary fibrosis.2025Gene
  8. Fei Wei formula attenuates pulmonary fibrosis by inhibiting lactate-driven endothelial mesenchymal transition via its target of HSP90ab1.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  9. The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study.2024Pulmonary pharmacology & therapeutics
  10. Aldehyde Dehydrogenase 2 Deficiency Aggravates Lung Fibrosis through Mitochondrial Dysfunction and Aging in Fibroblasts.2024The American journal of pathology
  11. USP13 Deficiency Impairs Autophagy and Facilitates Age-related Lung Fibrosis.2023American journal of respiratory cell and molecular biology
  12. Imbalanced distribution of regulatory T cells and Th17.1 cells in the peripheral blood and BALF of sarcoidosis patients: relationship to disease activity and the fibrotic radiographic phenotype.2023Frontiers in immunology
  13. Association of family sequence similarity gene 13A gene polymorphism and interstitial lung disease susceptibility: A systematic review and meta-analysis.2023Molecular genetics & genomic medicine
  14. External validation of the GAP model in Chinese patients with idiopathic pulmonary fibrosis.2023The clinical respiratory journal
  15. Small airway dysfunction in Chinese patients with idiopathic pulmonary fibrosis.2022BMC pulmonary medicine
  16. IL-17A promotes lung fibrosis through impairing mitochondrial homeostasis in type II alveolar epithelial cells.2022Journal of cellular and molecular medicine
  17. Every road leads to Rome: therapeutic effect and mechanism of the extracellular vesicles of human embryonic stem cell-derived immune and matrix regulatory cells administered to mouse models of pulmonary fibrosis through different routes.2022Stem cell research & therapy
  18. Krebs von den Lungen-6 levels in untreated idiopathic pulmonary fibrosis.2022The clinical respiratory journal
  19. Coronavirus disease 2019-associated pulmonary fibrosis: clinical findings, pathogenesis, and potential treatment.2021Chinese medical journal
Chinese-language papers (not in the count)1
  1. [Research status of diagnosis, treatment and prognosis of primary Sjögren's syndrome-associated interstitial lung disease].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
Earlier papers (2016–2020)11
  1. ATF4 Mediates Mitochondrial Unfolded Protein Response in Alveolar Epithelial Cells.2020American journal of respiratory cell and molecular biology
  2. Idiopathic Pulmonary Fibrosis Registry China study (PORTRAY): protocol for a prospective, multicentre registry study.2020BMJ open
  3. Direct medical costs of hospitalized patients with idiopathic pulmonary fibrosis in a tertiary hospital in China.2020Chinese medical journal
  4. Current therapies for patients with acute exacerbation of idiopathic pulmonary fibrosis.2020Chinese medical journal
  5. IL-25/IL-33/TSLP contributes to idiopathic pulmonary fibrosis: Do alveolar epithelial cells and (myo)fibroblasts matter?2020Experimental biology and medicine (Maywood, N.J.)
  6. Water-Soluble C60 Protects Against Bleomycin-Induced Pulmonary Fibrosis in Mice.2020International journal of nanomedicine
  7. Chinese herbal medicines for the treatment of cough in idiopathic pulmonary fibrosis: A protocol for systematic review and meta-analysis.2020Medicine
  8. Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome.2019European radiology
  9. Alterations to the Lung Microbiome in Idiopathic Pulmonary Fibrosis Patients.2019Frontiers in cellular and infection microbiology
  10. Serum prealbumin is a prognostic indicator in idiopathic pulmonary fibrosis.2019The clinical respiratory journal
  11. [Differences in small airway lesions in patients with different types of idiopathic interstitial pneumonia].2019Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status12
  1. Confirmatory Clinical Study of HEC585 Tablets in Patients With IPFRecruitingNCT07082842Study sitePhase 3Start 2025-10
  2. A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07464912Study sitePhase 3Start 2025-12
  3. A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary FibrosisNot yet recruitingNCT07719023Study sitePhase 3Start 2026-08
  4. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  5. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  6. A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis SubjectsCompletedNCT05895565Study sitePhase 1Start 2023-05
  7. Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary FibrosisCompletedNCT05722964Study sitePhase 2Start 2023-03
  8. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05321069Study sitePhase 3Start 2022-10
  9. A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary FibrosisStatus unknownNCT05424887Study sitePhase 2Start 2022-07
  10. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  11. Phase ll Study of HEC585 in Patients With IPFActive, not recruitingNCT05060822Study sitePhase 2Start 2021-06
  12. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Study sitePhase 3Start 2019-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led no English-language PubMed papers on lymphangioleiomyomatosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Beijing for lymphangioleiomyomatosis28 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [A case of diffuse cystic lung disease with severe pulmonary hypertension in a reproductive-aged female].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led 1 of the 55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025: 1.8%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

8 hospitals in Beijing for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

11 hospitals in Beijing for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led no English-language PubMed papers on Pompe disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Beijing for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Pulmonary Hypertension in Glycogen Storage Disease Type II.2018Chinese medical journal

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

11 hospitals in Beijing for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Bilateral Cerebral Infarctions and Intracardiac Thrombus in a Young Duchenne Muscular Dystrophy Patient.2018Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 9 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 1.2%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 3320242025: 332025

32 hospitals in Beijing for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrologyPathology / laboratory medicine
Papers it led9
  1. Crosstalk Between Th17 Cells and Renal Tubular Epithelial Cells Promotes Fibrotic Progression in IgA Nephropathy.2025Current medical science
  2. How to identify IgA nephropathy presenting as nephrotic syndrome coexisting with minimal change disease? A 15-year single-center clinicopathological analysis.2025Frontiers in immunology
  3. IgA nephropathy, non-cirrhotic portal fibrosis, and POEMS syndrome: A rare combination in the long-term follow-up of Sjögren's syndrome.2025The Journal of international medical research
  4. The prognostic role of activation of the complement pathways in the progression of advanced IgA nephropathy to end-stage renal disease.2024BMC nephrology
  5. Complement C3a/C3aR and C5a/C5aR deposits accelerate the progression of advanced IgA nephropathy to end-stage renal disease.2024Clinical and experimental medicine
  6. Genetic Loci of the Renin-Angiotensin System and IgA Nephropathy.2024Genetic testing and molecular biomarkers
  7. Retroperitoneal laparoscopic renal biopsy: an 8 year experience at a single centre.2023International urology and nephrology
  8. Crescents proportions above 10% are associated with unfavorable kidney outcomes in IgA nephropathy patients with partial crescent formation.2023Renal failure
  9. IgA Nephropathy with Macroproteinuria and a GFR of 20-30 ml/min/1.73 m2 May Still Benefit from RAS Inhibition.2022Journal of the renin-angiotensin-aldosterone system : JRAAS
Earlier papers (2016–2020)7
  1. Efficacy and safety of immunosuppressive treatment in IgA nephropathy: a meta-analysis of randomized controlled trials.2019BMC nephrology
  2. High-throughput sequencing analysis of genes encoding the B-lymphocyte receptor heavy-chain CDR3 in renal and peripheral blood of IgA nephropathy.2019Bioscience reports
  3. Expression of the intrarenal angiotensin receptor and the role of renin-angiotensin system inhibitors in IgA nephropathy.2019Molecular and cellular biochemistry
  4. Outcomes of normotensive IgA nephropathy patients with mild proteinuria who have impaired renal function.2019Renal failure
  5. Comparative Analyses of Subgingival Microbiome in Chronic Periodontitis Patients with and Without IgA Nephropathy by High Throughput 16S rRNA Sequencing.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  6. Outcomes of IgA Nephropathy with Segmental Glomerular Necrosis But without Crescent Formation.2016American journal of nephrology
  7. [The clinical study of IgA nephropathy with severe chronic periodontitis and aggressive periodontitis].2016Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

16 hospitals in Beijing for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)
Papers it led1
  1. The causal effects of primary biliary cholangitis on irritable bowel syndrome: a mendelian randomization study.2025International journal of surgery (London, England)
Earlier papers (2016–2020)1
  1. Interstitial granulomatous dermatitis associated with primary biliary cirrhosis.2018The Journal of dermatology
All its trials on ClinicalTrials.gov, any status1
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

10 hospitals in Beijing for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)2
  1. Differentiation of benign and malignant hilar bile duct stenosis.2016The Journal of surgical research
  2. [Isolated IgG4-related sclerosing cholangitis].2016Zhonghua yi xue za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Beijing for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中日友好医院

China-Japan Friendship Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Jiangxi Hospital of China-Japan Friendship Hospital; China-Japan FriendshipHospital; China-Japan Friendship Hospital of Jilin University; College of China-Japan Friendship Hospital; CJFH

Suggest a correctionDownload the data